Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down

Sanofi (SNY) reported Q2 2025 adjusted earnings of $0.90 per share and sales of $11.33 billion, both missing consensus estimates, despite 10.1% constant currency revenue growth. Strong performance from key drugs, notably Dupixent with 21.1% sales growth to €3.83 billion, and significant contributions from new products like Altuviiio and vaccines, including a 322.2% surge for Beyfortus, underpinned the top-line expansion. While the earnings miss led to a pre-market stock decline of over 4%, Sanofi raised its 2025 sales guidance to high single-digit CER growth, reaffirming low double-digit earnings growth, highlighting confidence in its pipeline and strategic M&A activities.

Analysis

Sanofi's second-quarter 2025 results present a dichotomy between headline misses and strong underlying operational performance. The company missed consensus estimates with an adjusted EPS of $0.90 and sales of $11.33 billion, triggering an initial negative stock reaction of over 4% in pre-market trading. However, this masks a robust 10.1% year-over-year sales growth at constant currency rates (CER), underpinned by standout performance in key growth areas. The immunology blockbuster Dupixent continues its impressive trajectory, with sales rising 21.1% to €3.83 billion, beating estimates and driven by strong demand across its expanding list of approved indications. The vaccine portfolio also exceeded expectations, growing 10.3%, fueled by a 322.2% surge in sales for the RSV antibody Beyfortus. Furthermore, newly launched products are becoming significant contributors, with the rare blood disorder drug Altuviiio on a clear path to blockbuster status in 2025. This growth successfully counteracts headwinds from generic competition impacting drugs like Aubagio (down 29.0%) and declines in some legacy rare disease products. Management's confidence is reflected in their decision to raise full-year 2025 sales guidance to "high single-digit" CER growth while reaffirming a "low double-digit" CER earnings growth outlook, signaling a positive forward view despite the quarterly miss.

Key Decisions for Investors

• Investors should look beyond the headline earnings miss and the initial negative stock reaction, focusing instead on the strong 10.1% constant-currency sales growth and the upgraded full-year revenue guidance as key indicators of fundamental health.
• The investment thesis remains heavily dependent on the sustained hyper-growth of Dupixent and the successful commercialization of new products like Altuviiio and Beyfortus to offset predictable declines in the legacy portfolio; upcoming FDA decisions later this year represent key catalysts.
• Consider the company's strategic pivot towards innovative pharmaceuticals, evidenced by recent M&A activity and the partial divestiture of its consumer health business, as a long-term positive that, combined with the ongoing €5 billion share buyback, could support valuation.